UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis

被引：0
|
作者：
Kaminski, H. [1 ]
Zhao, C. [2 ]
zu Horste, G. Meyer [3 ]
O'Connor, K. [4 ]
Klingelschmitt, G. [5 ]
Krumova, P. [5 ]
Bolt, S. [6 ]
Vodopivec, I. [5 ]
Murai, H. [7 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Fudan Univ, Shanghai, Peoples R China
[3] Univ Munster, Munster, Germany
[4] Yale Univ, New Haven, CT USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod, Welwyn Garden City, Herts, England
[7] Univ Hlth & Welf, Narita, Japan
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.162
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.92
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [11] A STUDY OF ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY IN PATIENTS WITH JUVENILE MYASTHENIA-GRAVIS
    MIZUNO, Y
    KAGA, M
    MISHIRO, M
    BRAIN & DEVELOPMENT, 1981, 3 (02): : 236 - 236
  • [12] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [13] Targeting the IL-6 receptor with the monoclonal antibody tocilizumab significantly improves quality of life in patients with rheumatoid arthritis
    Smolen, J.
    Atkins, C.
    Rovensky, J.
    Ramos-Remus, C.
    Lucero, M.
    Woodworth, T.
    Alten, R.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1181 - 1182
  • [14] IL-6 Receptor Antibody Preferentially Affects Tumors in the Repopulation Phase of Growth
    Sura, K.
    Galoforo, S.
    Buelow, K.
    Dabjan, M.
    Grills, I. S.
    Wilson, G. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E187 - E187
  • [15] TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
    Howard, J.
    Vu, T.
    Bril, V.
    Peric, S.
    Verschuuren, J.
    Mantegazza, R.
    Murai, H.
    Ulrichts, P.
    Guglietta, A.
    de Haard, H.
    Parys, W.
    Beydoun, S.
    Pasnoor, M.
    Karam, C.
    Muppidi, Sr
    Bertorini, T.
    Bhavaraju-Sanka, R.
    Li, Y.
    MUSCLE & NERVE, 2020, 62 : S125 - S126
  • [16] Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study
    Nowak, Richard J.
    Coffey, Christopher S.
    Goldstein, Jonathan M.
    Dimachkie, Mazen M.
    Benatar, Michael
    Kissel, John T.
    Wolfe, Gil, I
    Burns, Ted M.
    Freimer, Miriam L.
    Nations, Sharon
    Granit, Volkan
    Smith, A. Gordon
    Richman, David P.
    Ciafaloni, Emma
    Al-Lozi, Muhammad T.
    Sams, Laura Ann
    Quan, Dianna
    Ubogu, Eroboghene
    Pearson, Brenda
    Sharma, Aditi
    Yankey, Jon W.
    Uribe, Liz
    Shy, Michael
    Amato, Anthony A.
    Conwit, Robin
    O'Connor, Kevin C.
    Hafler, David A.
    Cudkowicz, Merit E.
    Barohn, Richard J.
    NEUROLOGY, 2022, 98 (04) : E376 - E389
  • [17] Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
    Howard Jr, James F.
    Bresch, Saskia
    Genge, Angela
    Hewamadduma, Channa
    Hinton, John
    Hussain, Yessar
    Juntas-Morales, Raul
    Kaminski, Henry J.
    Maniaol, Angelina
    Mantegazza, Renato
    Masuda, Masayuki
    Sivakumar, Kumaraswamy
    Smilowski, Marek
    Utsugisawa, Kimiaki
    Vu, Tuan
    Weiss, Michael
    Zajda, Malgorzata
    Boroojerdi, Babak
    Brock, Melissa
    de la Borderie, Guillemette
    Duda, Petra W.
    Lowcock, Romana
    Vanderkelen, Mark
    Leite, M. Isabel
    LANCET NEUROLOGY, 2023, 22 (05): : 395 - 406
  • [18] Efficacy and safety of eculizumab in patients with treatmentrefractory anti-acetylcholine receptor antibody-positive generalised myasthenia gravis previously treated with rituximab
    Patti, Francesco
    Mozaffar, Tahseen
    Yountz, Marcus
    O'Brien, Fanny
    Siddiqi, Zaeem
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [19] Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis
    Perez-Ruixo, Juan-Jose
    Zhu, Yaowei
    Neyens, Martine
    Jouvin, Marie-Helene
    Ramchandren, Sindhu
    Xu, Yan
    Leu, Jocelyn
    Dosne, Anne-Gaelle
    Xiong, Yuan
    Valenzuela, Belen
    Ling, Leona
    Nandy, Partha
    Sun, Hong
    NEUROLOGY, 2023, 100 (17)
  • [20] CORRELATION BETWEEN MYASTHENIA GRAVIS-ACTIVITIES OF DAILY LIVING (MG-ADL) AND QUANTITATIVE MYASTHENIA GRAVIS (QMG) ASSESSMENTS OF ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE REFRACTORY GENERALIZED MYASTHENIA GRAVIS IN THE PHASE 3 REGAIN STUDY
    Vissing, John
    O'Brien, Fanny
    Wang, Jing Jing
    Howard, James F., Jr.
    MUSCLE & NERVE, 2018, 58 (02) : E21 - E22
12345